Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer (Protocol)
Publication date
2020-12
Authors
Lebbink, C. A.
Lentjes, Eef G W
Tissing, W.J.E.
van den Heuvel-Eibrink, Marry M
Van Santen, Hanneke M.
van Dalen, Elvira C
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.
Keywords
Taverne, Pharmacology (medical)
Citation
Lebbink, C, Lentjes, E, Tissing, W, van den Heuvel-Eibrink, M M, van Santen, HM & van Dalen, E C 2020, 'Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer (Protocol)', Cochrane Database of Systematic Reviews , vol. 2020, no. 12, CD013805, pp. 1-9. https://doi.org/10.1002/14651858.CD013805